Cancer Health Outcomes and Control
The Cancer Health Outcomes and Control Research Program (CO) is a new program in the Vanderbilt-Ingram Cancer Center (VICC) with overall focus to decrease the burden of cancer across the entire care continuum, including:
The healthy and at-risk
Cancer patients undergoing therapy
We will achieve this by developing a well-integrated program of systematic, hypothesis-driven, interdisciplinary research, education and advocacy linked to public health and clinical care. In pursuing these objectives, CO is closely allied with other programs within the VICC, including our population science partner program, Cancer Epidemiology (CE) and the basic and clinical science programs to facilitate inter-programmatic collaboration. In addition, we have extensive collaborations with community partners, including Meharry Medical College (MMC), Tennessee State University (TSU), federally qualified community health centers and oncologists at our affiliate institutions, through the Vanderbilt Health Affiliate Network (VHAN) and with other academic centers to further impact in the community and foster multi-institution research.
The scientific goals of the CO Research Program center upon three somewhat overlapping themes along the cancer control continuum:
- Prevention and Early Detection
- Treatment-Related Outcomes
- Survivorship and Palliative Care
These goals will be met by addressing the following specific aims:
To establish and further develop population and community-based resources for research into prevention, short and long-term outcomes of cancer
To identify environmental, sociobehavioral and genetic factors which may influence the short- and long-term outcomes of cancer
To identify the incidence, prevalence, spectrum, and severity of adverse long-term patient-centered outcomes following cancer diagnosis and treatment and develop interventions to prevent or ameliorate such outcomes
To assess the magnitude and determinants of disparities in cancer control and outcomes associated with age, race, gender, geography and other group characteristics and develop interventions to decrease such disparities
To translate our population-based research to the clinic and the community to improve the lives of patients and families living with through and after cancer
Debra L. Friedman, M.D., M.S., Co-leader, is the E. Bronson Ingram Chair in Pediatric Oncology, Associate Professor of Pediatrics, the Director for the Division of Pediatric Hematology/Oncology and the Director of the REACH for Survivorship Program at VICC. Since her arrival at Vanderbilt in 2008, she has served as the co-leader of the VICC Cancer Epidemiology, Prevention and Control Research Program (CEPC), with Dr. Wei Zheng (See Section 1.3). Dr. Friedman was previously faculty at the Fred Hutchinson Cancer Research Center, where she served as the first Director of Survivorship and the Principal Investigator of the Livestrong Survivorship Center of Excellence. Dr. Friedman’s research interests lie in supportive oncology during cancer therapy, in the long-term outcomes for cancer survivors, as well as in the design of novel therapeutic protocols for childhood cancer, designed to decrease adverse long-term effects of therapy. She is an internationally recognized expert in cancer survivorship, participating in projects evaluating best practices and models of care. She is investigating a diverse group of physiologic and psychosocial short and long-term outcomes among cancer survivors. Dr. Friedman has leadership roles in survivorship, pediatric, adolescent and young adult oncology in the Children’s Oncology Group (COG). She is currently the Principal or co-investigator of six NCI, PCORI or foundation-funded grants examining outcomes for cancer survivors, as well as an NCI-funded T32 training grant in pediatric oncology. Dr. Friedman serves on the Internal Scientific Advisory Committee of the Meharry Medical College (MMC)/VICC Partnership (U54/NCI: Adunyah, /Moses/Whalen, PIs), bringing expertise in the area of cancer control and survivorship to that partnership and cancer health disparities back to VICC.
David F. Penson, M.D., M.P.H., Co-Leader, is the Hamilton and Howard Chair in Urologic Oncology, Professor of Urologic Surgery and Medicine and Director of the Center of Surgical Quality and Outcomes Research. Dr. Penson’s research efforts focus on the assessment of long-term patient-centered outcomes in prostate cancer (PCa). He is specifically focused on the comparative effectiveness of therapies for localized PCa. He is the principal investigator of two of the largest population-based prospective cohorts of prostate cancer survivors in the world. The Prostate Cancer Outcomes Study (PCOS), funded by NCI, included roughly 3600 men diagnosed with PCa in 1994-1995 followed prospectively for 15 years. The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study enrolled 3700 men, of whom approximately 25% are racial and ethnic minorities, diagnosed in 2011-12 and was funded by three grants from the US Agency for Healthcare Quality and Research (AHRQ) and the Patients-Centered Outcomes Research Institute (PCORI). Both grants include extensive patient-reported outcomes, such as health-related quality of life, as endpoints. In addition, Dr. Penson is a co-PI or co-investigator on two additional NCI and CDC-funded studies focused on cancer control and outcomes in PCa. Dr. Penson serves in a number of national leadership roles related to research and health care policy, including the Health Services Outcomes and Delivery (HSOD) study section of NIH CSR and the National Advisory Council for AHRQ. He is the current Chair for Health Policy for the American Urological Association and a past member of the American College of Surgeon’s Commission on Cancer.